Resumen

LOUVISON, Marília Cristina Prado; BERSUSA, Ana Aparecida Sanches; PSALTIKIDIS, Eliane Molina  y  NASCIMENTO, Andréia. Teriparatide for the treatment of osteoporosis in postmenopausal women assisted by the Brazilian Public Health System. BIS, Bol. Inst. Saúde (Impr.) [online]. 2013, vol.14, n.2, pp. 195-203. ISSN 1518-1812.

Osteoporosis is a systemic disease characterized by low bone mass and micro-architectural deterioration of bone tissue, which increases the risk of bone fractures. There is a vast therapeutic arsenal for its treatment. However, in the State of São Paulo there are lawsuits to obtain the teriparatide. The drug stimulates the formation of new bone tissue and is not selected by use in the Brazilian Public Health System (SUS). A systematic review was conducted aiming to contribute to the rational use of teriparatide, and included studies published from 2008, in postmenopausal women with osteoporosis, considering fractures and bone mineral density (BMD) as outcomes. Evidence indicates superior efficacy of teriparatide compared to sodium alendronate, considering the reduction of fractures only in postmenopausal patients with severe osteoporosis and previous fractures. For women at different degrees of osteoporosis, however, there is evidence of better results as teriparatide only for BMD, as compared to sodium alendronate or placebo. Teriparatide should be recommended as an alternative to bisphosphonates only for postmenopausal women with severe osteoporosis, osteoporotic fractures or post-treatment failure with conventional, for a maximum period of 2 years.

Palabras llave : Osteoporosis; Teriparatide; Human Parathyroid Hormone.